Beta-blockers are about as ordinary as medications get. Tens of millions of people take them for high blood pressure, and most never think twice about it. So it might come as a surprise that when economist Robert J. Brent ran the numbers on beta-blockers and dementia, he found a genuinely split result one that’s almost a parable for why “does it work” and “should we pay for it” are two very different questions.

The good news first

Beta-blockers are prescribed to manage hypertension, which is a major driver of vascular dementia, the kind caused by restricted blood flow to the brain. So the logical hope is that beta-blockers, by controlling blood pressure, would also ease dementia symptoms. Brent’s research, drawn from a large national dataset tracking real patients over time, confirmed it: beta-blockers modestly reduced dementia symptoms across the board.

Run that reduction through the same rigorous cost-benefit math used throughout the book, translating symptom improvement into life-years saved, then into dollar terms using the standard $3.27 million value of a statistical life, and beta-blockers come out ahead as a pure dementia intervention. Once you subtract the roughly $800 lifetime cost of the medication, treating beta-blockers purely as a dementia treatment nets a small but real gain of a few hundred dollars per person.

As a story about treating cognitive decline, that’s a win.

Then the other shoe drops

But nobody takes a blood pressure medication only to affect their dementia symptoms. It also does the thing it’s actually prescribed for: it changes blood pressure, heart function, and, it turns out, mortality risk, in ways that go well beyond the brain.

When Brent’s team measured the direct effect of beta-blockers on mortality, separate from their effect on dementia, the number was large and negative: a loss of roughly $20,600 per person. That single figure overwhelms the modest dementia-related gain many times over. Add it all up, and the full picture for beta-blockers as a hypertension treatment for older adults with dementia is a net loss of nearly $20,000 per person.

The team didn’t stop there. Suspecting the result might be an artifact of the specific dementia measurement used (the CDR scale), they reran the entire analysis using a completely different tool: the Mini-Mental State Exam, the 11-question cognitive test used in clinics worldwide. Same story: a positive effect on dementia, wiped out by a larger negative effect on mortality overall.

Why would a heart medication hurt older patients?

The book points to two plausible explanations, both grounded in the existing medical literature. First, beta-blockers are prescribed far more broadly than the evidence actually supports; they’re not recommended for uncomplicated high blood pressure without a prior heart attack, and they carry known metabolic side effects, including weight gain and reduced insulin sensitivity, that raise the risk of diabetes by roughly a third compared to other blood pressure treatments.

Second, and perhaps more importantly, older bodies respond to blood pressure medication differently than younger ones. Aging arteries lose flexibility and gain resistance, which is the opposite pattern from younger patients, meaning a drug well-suited to a 45-year-old’s cardiovascular system may be poorly suited to a 75-year-old’s. The research even points to increased stroke risk as part of the pattern.

The real lesson here isn’t about beta-blockers

It’s about what happens when you only measure one thing. If Brent’s team had stopped at “does it reduce dementia symptoms,” beta-blockers would have looked like a modest success story. It’s only by widening the lens to the full picture of costs and consequences that the true trade-off becomes visible, and in this case, the trade-off is a bad one for the average older patient in the data.

This is exactly why “effective” and “worth it” aren’t the same word. A treatment can genuinely help with one specific symptom and still be a net negative once every consequence is counted. That’s not a reason for panic, and it’s certainly not medical advice to stop a prescribed medication; that conversation belongs with a doctor. But it is a reason to ask, at the population level, whether a decades-old default prescribing habit still holds up under modern scrutiny.